AI Summary

Researchers completed the first clinical trial of activated regulatory T cells (ATregs, marketed as Actileucel), derived from healthy donors’ white blood cells, to prevent graft‑versus‑host disease after allogeneic stem cell transplantation. The Phase I/II study showed the cells can be manufactured within 24 hours and infused immediately, with administration proving safe and well‑tolerated by participants. These findings, reported in Transplantation and Cellular Therapy, suggest a feasible pathway toward a broadly accessible cell‑based prophylaxis for this severe post‑transplant complication.

AI summaries can be wrong sometimes—always verify important details using the source article.